GILEAD SCIENCES INC (NASDAQ: GILD)

GILEAD SCIENCES INC

NASDAQ: GILD (Gilead Sciences, Inc.)

最近更新时间: 15 May, 2:22PM

99.81

1.43 (1.45%)

加入群组

前收盘价格	98.38
收盘价格	99.53
成交量	5,440,691
平均成交量 (3个月)	9,895,855
市值	124,263,440,384

市盈率 (P/E TTM)	20.97
预期市盈率 (P/E Forward)	13.57
价格/销量 (P/S)	4.70
股市价格/股市净资产 (P/B)	6.97

52周波幅	62.07 (-37%) — 119.96 (20%)
利润日期	6 Aug 2025 - 11 Aug 2025
股息率 (DY TTM)	3.11%

市场趋势

		短期	中期
行业	Drug Manufacturers - General (US)	看跌	混合的
	Drug Manufacturers - General (全球的)	看跌	混合的
股票	Gilead Sciences, Inc.	看涨	看涨

AIStockmoo 评分

2.2

分析师共识	4.0
内部交易活动	-2.5
价格波动	2.0
技术平均移动指标	3.5
技术振荡指标	4.0
平均	2.20

相关股票

股票	市值	DY	P/E（TTM）	P/B
GILD	124 B	3.11%	20.97	6.97
AMGN	143 B	3.48%	24.26	24.96
AZN	220 B	2.20%	28.38	6.19
SNY	127 B	8.05%	20.32	1.61
GRFS	6 B	-	28.00	0.740
BIIB	17 B	-	11.68	1.07

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
部门	Healthcare
行业	Drug Manufacturers - General
投资方式	Large Value
内部持股比例	0.12%
机构持股比例	89.63%

52周波幅	62.07 (-37%) — 119.96 (20%)
目标价格波幅	125.00 (25%) — 140.00 (40%)
高	140.00 (Wells Fargo, 40.27%)	购买
中	128.00 (28.24%)
低	125.00 (Oppenheimer, 25.24%)	购买
	125.00 (Cantor Fitzgerald, 25.24%)	购买
平均值	130.17 (30.42%)
总计	6 购买
平均价格@调整类型	108.98

公司	日期	目标价格	调整类型	价格@调整类型
Morgan Stanley	25 Apr 2025	135.00 (35.26%)	购买	103.17
Morgan Stanley	11 Mar 2025	130.00 (30.25%)	购买	114.43
Oppenheimer	25 Apr 2025	125.00 (25.24%)	购买	103.17
Oppenheimer	04 Mar 2025	132.00 (32.25%)	购买	114.74
Cantor Fitzgerald	22 Apr 2025	125.00 (25.24%)	购买	105.51
JP Morgan	27 Mar 2025	130.00 (30.25%)	购买	111.16
B of A Securities	05 Mar 2025	126.00 (26.24%)	购买	115.44
Wells Fargo	05 Mar 2025	140.00 (40.27%)	购买	115.44

名称	平均购买 ($)	平均卖出 ($)	总净额	总净值 ($)
MERCIER JOHANNA	-	106.74	-28,000	-2,988,720
累积净数量				-28,000
累积净值 ($)				-2,988,720
累积平均购买 ($)				-
累积平均卖出 ($)				106.74

名称	持有人	日期	类型	数量	价格	价值 ($)
MERCIER JOHANNA	职员	22 May 2025	自动卖出 (-)	28,000	106.74	2,988,720
MERCIER JOHANNA	职员	22 May 2025	执行期权	25,000	-	-

日期	类型	细节
23 May 2025	公告	ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors
15 May 2025	公告	Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA
12 May 2025	CNBC	Trump's plan to slash drug prices may struggle to get off the ground – here's what to know
07 May 2025	公告	Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment
07 May 2025	公告	Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025
29 Apr 2025	公告	Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis
29 Apr 2025	公告	Gilead Sciences to Present at Upcoming Investor Conferences
28 Apr 2025	公告	Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development
24 Apr 2025	公告	Gilead Sciences Announces First Quarter 2025 Financial Results
24 Apr 2025	CNBC	Corporate America shelled out millions for Trump's inauguration. Now he's upending many of their businesses
21 Apr 2025	公告	Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer
10 Apr 2025	公告	Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025
12 Mar 2025	公告	Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
11 Mar 2025	公告	First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
显示更多

股息率 (DY TTM)	3.11%
5年平均股息收益率	3.80%
股息支付比率	65.13%
预计下次股息支付	Sep 2025

除息日	公告日期	支付日期	详情
13 Jun 2025	22 Apr 2025	27 Jun 2025	0.79 现金
14 Mar 2025	05 Feb 2025	28 Mar 2025	0.79 现金
13 Dec 2024	30 Oct 2024	30 Dec 2024	0.77 现金
13 Sep 2024	30 Jul 2024	27 Sep 2024	0.77 现金
14 Jun 2024	23 Apr 2024	27 Jun 2024	0.77 现金
14 Mar 2024	01 Feb 2024	28 Mar 2024	0.77 现金
14 Dec 2023	01 Nov 2023	28 Dec 2023	0.75 现金
14 Sep 2023	25 Jul 2023	28 Sep 2023	0.75 现金
14 Jun 2023	25 Apr 2023	29 Jun 2023	0.75 现金
14 Mar 2023	25 Jan 2023	30 Mar 2023	0.75 现金
14 Dec 2022	25 Oct 2022	29 Dec 2022	0.73 现金
14 Sep 2022	25 Jul 2022	29 Sep 2022	0.73 现金
14 Jun 2022	27 Apr 2022	29 Jun 2022	0.73 现金
14 Mar 2022	28 Jan 2022	30 Mar 2022	0.73 现金
14 Dec 2021	26 Oct 2021	30 Dec 2021	0.71 现金
14 Sep 2021	26 Jul 2021	29 Sep 2021	0.71 现金
14 Jun 2021	27 Apr 2021	29 Jun 2021	0.71 现金
12 Mar 2021	02 Feb 2021	30 Mar 2021	0.71 现金
14 Dec 2020	26 Oct 2020	30 Dec 2020	0.68 现金
14 Sep 2020	29 Jul 2020	29 Sep 2020	0.68 现金
11 Jun 2020	29 Apr 2020	29 Jun 2020	0.68 现金
12 Mar 2020	03 Feb 2020	30 Mar 2020	0.68 现金
12 Dec 2019	23 Oct 2019	30 Dec 2019	0.63 现金
12 Sep 2019	29 Jul 2019	27 Sep 2019	0.63 现金
13 Jun 2019	01 May 2019	27 Jun 2019	0.63 现金
14 Mar 2019	01 Feb 2019	28 Mar 2019	0.63 现金
13 Dec 2018	24 Oct 2018	28 Dec 2018	0.57 现金
13 Sep 2018	24 Jul 2018	27 Sep 2018	0.57 现金
14 Jun 2018	30 Apr 2018	28 Jun 2018	0.57 现金
15 Mar 2018	05 Feb 2018	29 Mar 2018	0.57 现金
14 Dec 2017	25 Oct 2017	28 Dec 2017	0.52 现金
14 Sep 2017	25 Jul 2017	28 Sep 2017	0.52 现金
14 Jun 2017	01 May 2017	29 Jun 2017	0.52 现金
14 Mar 2017	06 Feb 2017	30 Mar 2017	0.52 现金
13 Dec 2016	31 Oct 2016	29 Dec 2016	0.47 现金
14 Sep 2016	22 Jul 2016	29 Sep 2016	0.47 现金
14 Jun 2016	27 Apr 2016	29 Jun 2016	0.47 现金
14 Mar 2016	02 Feb 2016	30 Mar 2016	0.43 现金
14 Dec 2015	26 Oct 2015	30 Dec 2015	0.43 现金
14 Sep 2015	23 Jul 2015	29 Sep 2015	0.43 现金
12 Jun 2015	24 Apr 2015	29 Jun 2015	0.43 现金
显示更多

每年股息收益率

年份	每年总股息 ($)	频率/年份	收益率 %
2025	1.58	2	1.58
2024	3.08	4	3.33
2023	3.00	4	3.70
2022	2.92	4	3.40
2021	2.84	4	3.91
2020	2.72	4	4.67
2019	2.52	4	3.88
2018	2.28	4	3.65
2017	2.08	4	2.90
2016	1.84	4	2.57
2015	1.29	3	1.28
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

请登录以添加到您的群组

AI 建议策略模板

自定义的价格提醒

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

请登录以添加到您的群组

已实现利润	-
未实现利润	-
收到股息 2025	-
利润总额	-
平均回报	-
数量(购买)	-
平均价格(购买)	-
数量(卖出)	-
平均价格(卖出)	-

请登录以添加到您的群组

没有符合您标准的股票

营业毛利率	20.76%
营业利益率 (TTM)	38.49%
稀释每股收益 (EPS TTM)	4.76
季度收入增长率 (YOY)	-0.30%
季度盈利增长率 (YOY)	24.80%

总债务/股东权益 (D/E MRQ)	130.79%
流动比率 (MRQ)	1.37
营业现金流 (OCF TTM)	10.37 B
杠杆自由现金流 (LFCF TTM)	9.99 B

资产报酬率 (ROA TTM)	12.14%
股东权益报酬率 (ROE TTM)	32.65%

安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)